Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The most effective method to Help a Friend or family member Determined to have Cellular breakdown in the lungs - 2How to see the Ursids, the final meteor shower of 2025
- 3Dwayne ‘the Rock’ Johnson opens up about being the 'new guy' again — and why this moment feels like a new life
- 4Interstellar comet 3I/ATLAS' journey through our solar system, in photos
- 5Survey: Canteen Cups With Great Warm Protection Impact
- Pain at the pump for Hampton Roads residents
- Find the Future of Outsourcing: Exploring the Gig Economy
- Figure out How to Improve Your Stream Voyage with Remarkable Trips and Exercises
- We analyzed Philly street scenes and identified signs of gentrification using machine learning trained on longtime residents’ observations
- Concern for couple jailed in Tehran as British embassy closes
- Twelve injured near Beit Shemesh, reports of shrapnel impact in Eilat as Iran targets Israel
- 6 Well known Nissan Vehicles in the U.S.
- Flourishing as a Charitable Pioneer: Individual Encounters in Generosity
- Flourishing in a Cutthroat Work Market: Vocation Methodologies
